Double take: Novartis signs back-to-back licensing agreements

The premier investor event

January 11–13, 2027 | San Francisco, CAJanuary 19–20, 2027 | Digital Partnering

Double take: Novartis signs back-to-back licensing agreements

By Nnenna Ohaka, Reporter, Partnering and InvestmentShare

Related news

Venture Investors Shift Strategy Toward Refined Modalities, Women’s Health and Platform Discipline

Rare disease research

Stronger biological proof is reshaping how rare disease therapies are funded and developed

From Shanghai to the world: How Asia is leading global biopharma collaboration

Biogen's blueprint for collaboration in China's thriving pharma landscape